Evaluating a new injection combined with PD-1 for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This exploratory clinical study assesses the safety, tolerability, immune response, and preliminary efficacy of LM103 Injection when used alongside PD-1 therapy in patients with advanced solid tumors. The treatment regimen includes LM103 injection, IL-2 therapy, PD-1 therapy, fludarabine, and cyclophosphamide. Patients with advanced solid tumors that have not responded to standard treatments will be enrolled, and their tumors will be evaluated for potential surgical resection or biopsy. The study aims to gather data on how well this combination therapy works in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The expected survival time is not less than 3 months.
2. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-1.
3. Patients with advanced solid tumors confirmed by histology or cytology: advanced Melanoma, cervical cancer/ovarian cancer, head and neck squamous cell cancer, non-small cell lung cancer, esophageal cancer and other solid tumors that have failed standard treatment regimens, cannot tolerate standard treatment, refuse or do not have standard treatment regimens available.
4. The patient has lesions that can be used for surgical resection (\>1.5 cm3) or biopsy puncture (no less than 6 lesions) for LM103 manufacturing.
5. At least one measurable lesion as the target lesion after collecting tumor tissue from the patient (RECIST v1.1 criteria).
6. Laboratory tests results during the screening period indicate that the subjects have sufficient organ function.

Exclusion Criteria:

1. Have a medical history of other malignant tumors other than the disease under study in the past 5 years, except for malignant tumors that can be expected to recover after treatment (including but not limited to thyroid cancer, cervical Carcinoma in situ, basal or squamous cell skin cancer or Ductal carcinoma in situ of the breast treated by radical surgery).
2. LM103 received systematic therapy of antineoplastic drugs (including chemotherapy, small molecule targeted drug therapy, Hormone replacement therapy, etc.), or local antineoplastic therapy (such as radiotherapy, palliative radiotherapy for bone metastases\>2 weeks before the start of the study and intracranial stereotactic radiotherapy or resection of a single brain metastasis\>3 weeks before the start of the study were acceptable) within 4 weeks before LM103 infusion; Or received clinical investigational drugs or equipment treatment.
3. Adverse reactions caused by previous treatment have not recovered to CTCAE (version 5.0) level 1 or below (excluding hair loss and neurotoxicity, which have been determined by the researchers to be irreparable and level 2 hypothyroidism for a long time).
4. Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.

Where it's running

• Tianjin Beichen Hospital
  China, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: fenge L doctor
• Email: rosetea85@163.com
• Phone: 86+13821070272

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AK138D1 for advanced solid tumors

  We will try AK138D1 given by IV in adults with advanced solid tumors that haven't responded to standard treatments to find a safe dose and see if it can shrink tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang · NCT07281326

• PRaG-1 Plus PRaG Therapy with Radiation and Immunotherapy in Older Adults with Advanced Solid Tumors

  This study tests whether giving PRaG-1 Cordycepin tablets together with radiation, immune-boosting injections, and PD-1/PD-L1 inhibitors can help people aged 65 and older with advanced solid tumors.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07267234

• Cordycepin (PRaG-1) to raise CD8+ T‑cell counts after treatment for solid tumors

  This trial will test whether PRaG-1 (cordycepin) can raise low CD8+ T‑cell counts in adults who are tumor‑free after treatment for solid cancers.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07258160

• TC-G203 treatment for GPC3-positive advanced solid tumors

  This trial will test a single-dose TC-G203 cell therapy to see if it is safe and helps adults with GPC3-positive recurrent or metastatic solid tumors who have already tried other treatments.

  Recruiting Early Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07242417

• Urolithin A (MitoPure®) with immune checkpoint inhibitors for newly diagnosed solid tumors

  This trial tests whether taking urolithin A (MitoPure®) alongside first-line immune checkpoint inhibitor therapy changes immune responses in adults with newly diagnosed solid tumors.

  Recruiting Goethe University · Frankfurt · NCT07161310

• How the CES1 liver enzyme affects capecitabine levels in people with colorectal, gastric, or esophageal cancer

  This project will see if differences in the CES1 enzyme change how capecitabine is processed and whether that affects side effects like hand‑foot syndrome in adults starting capecitabine with oxaliplatin for colorectal, gastric, or esophageal cancer.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07114627

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.